Link Between GLP-1 Receptor Agonists and Nonarteritic Anterior Ischemic Optic Neuropathy in Older Adults
A recent study links GLP-1 receptor agonists, common diabetes medications, with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) in older adults, highlighting the need for vigilant eye health monitoring.
Recent research reveals a potential association between the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a common class of diabetes medications, and the development of nonarteritic anterior ischemic optic neuropathy (NAION) in older adults with type 2 diabetes. The study, published in JAMA Ophthalmology, analyzed data from over 3.8 million Medicare patients aged 65 and above, finding that those prescribed GLP-1 RAs had a modest but significant increased risk of NAION compared to patients on other antidiabetic treatments.
The investigation focused on several widely used GLP-1 RAs, including dulaglutide, semaglutide, liraglutide, and exenatide. The researchers observed that 7,660 patients developed NAION over a median follow-up period of approximately 3.7 years. Notably, patients on semaglutide and liraglutide showed a higher hazard ratio for developing this optic nerve condition, with risks increased by 39% and 25%, respectively.
NAION is a sight-threatening condition caused by poor blood flow to the optic nerve, leading to sudden vision loss. While the exact mechanism linking GLP-1 RAs and NAION remains unclear, the findings suggest that physicians should monitor visual health in patients prescribed these medications, especially those with pre-existing risk factors.
As GLP-1 RAs are increasingly prescribed for managing type 2 diabetes due to their effectiveness and weight loss benefits, this study emphasizes the need for further research to understand the causative relationship and to develop strategies for risk mitigation. Healthcare providers should weigh the benefits and potential risks when considering GLP-1 RAs in older patients.
This research underscores the importance of vigilance in managing diabetic treatments and highlights the necessity for ongoing investigation into medication-related ocular risks.
Source: https://medicalxpress.com/news/2025-08-glp-receptor-agonist-linked-nonarteritic.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Providing Cash Incentives to New Mothers Enhances Breastfeeding Rates, Study Shows
Unconditional cash transfers to new mothers in the U.S. significantly increase breastfeeding rates without affecting postpartum mood, offering promising avenues for improving maternal health outcomes.
Virtual Reality Nature Scenes Show Promise in Reducing Pain Sensitivity
Virtual reality immersion in natural scenes has been shown to reduce pain sensitivity, especially when users feel a strong sense of presence, offering promising new avenues for pain management.
Australia Launches New National Immunization Strategy to Improve Vaccination Rates
Australia's new National Immunization Strategy aims to reverse declining vaccination rates and strengthen community trust, access, and data-driven decision-making for better public health outcomes.
Innovative Personalized Cancer Vaccines Show Promise in Reducing Tumor Recurrence in Mouse Models
University of Wisconsin–Madison researchers have developed personalized cancer vaccines that target tumor remnants, significantly reducing recurrence in mouse models and offering new hope for highly aggressive cancers.